BH3-mimetics: recent developments in cancer therapy

Abstract The hopeful outcomes from 30 years of research in BH3-mimetics have indeed served a number of solid paradigms for targeting intermediates from the apoptosis pathway in a variety of diseased states. Not only have such rational approaches in drug design yielded several key therapeutics, such...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paul A. Townsend, Maria V. Kozhevnikova, Olivier N. F. Cexus, Andrey A. Zamyatnin, Surinder M. Soond
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Apoptosis BH-3 mimetics PUMA-mimetics Smac-mimetics Bcl-xL-mimetics Noxa-mimetics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8ca444f31899451e9516bb1912adb4ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ca444f31899451e9516bb1912adb4ea
record_format	dspace
spelling	oai:doaj.org-article:8ca444f31899451e9516bb1912adb4ea2021-11-14T12:15:27ZBH3-mimetics: recent developments in cancer therapy10.1186/s13046-021-02157-51756-9966https://doaj.org/article/8ca444f31899451e9516bb1912adb4ea2021-11-01T00:00:00Zhttps://doi.org/10.1186/s13046-021-02157-5https://doaj.org/toc/1756-9966Abstract The hopeful outcomes from 30 years of research in BH3-mimetics have indeed served a number of solid paradigms for targeting intermediates from the apoptosis pathway in a variety of diseased states. Not only have such rational approaches in drug design yielded several key therapeutics, such outputs have also offered insights into the integrated mechanistic aspects of basic and clinical research at the genetics level for the future. In no other area of medical research have the effects of such work been felt, than in cancer research, through targeting the BAX-Bcl-2 protein-protein interactions. With these promising outputs in mind, several mimetics, and their potential therapeutic applications, have also been developed for several other pathological conditions, such as cardiovascular disease and tissue fibrosis, thus highlighting the universal importance of the intrinsic arm of the apoptosis pathway and its input to general tissue homeostasis. Considering such recent developments, and in a field that has generated so much scientific interest, we take stock of how the broadening area of BH3-mimetics has developed and diversified, with a focus on their uses in single and combined cancer treatment regimens and recently explored therapeutic delivery methods that may aid the development of future therapeutics of this nature.Paul A. TownsendMaria V. KozhevnikovaOlivier N. F. CexusAndrey A. ZamyatninSurinder M. SoondBMCarticleApoptosisBH-3 mimeticsPUMA-mimeticsSmac-mimeticsBcl-xL-mimeticsNoxa-mimeticsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-33 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Apoptosis BH-3 mimetics PUMA-mimetics Smac-mimetics Bcl-xL-mimetics Noxa-mimetics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Apoptosis BH-3 mimetics PUMA-mimetics Smac-mimetics Bcl-xL-mimetics Noxa-mimetics Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Paul A. Townsend Maria V. Kozhevnikova Olivier N. F. Cexus Andrey A. Zamyatnin Surinder M. Soond BH3-mimetics: recent developments in cancer therapy
description	Abstract The hopeful outcomes from 30 years of research in BH3-mimetics have indeed served a number of solid paradigms for targeting intermediates from the apoptosis pathway in a variety of diseased states. Not only have such rational approaches in drug design yielded several key therapeutics, such outputs have also offered insights into the integrated mechanistic aspects of basic and clinical research at the genetics level for the future. In no other area of medical research have the effects of such work been felt, than in cancer research, through targeting the BAX-Bcl-2 protein-protein interactions. With these promising outputs in mind, several mimetics, and their potential therapeutic applications, have also been developed for several other pathological conditions, such as cardiovascular disease and tissue fibrosis, thus highlighting the universal importance of the intrinsic arm of the apoptosis pathway and its input to general tissue homeostasis. Considering such recent developments, and in a field that has generated so much scientific interest, we take stock of how the broadening area of BH3-mimetics has developed and diversified, with a focus on their uses in single and combined cancer treatment regimens and recently explored therapeutic delivery methods that may aid the development of future therapeutics of this nature.
format	article
author	Paul A. Townsend Maria V. Kozhevnikova Olivier N. F. Cexus Andrey A. Zamyatnin Surinder M. Soond
author_facet	Paul A. Townsend Maria V. Kozhevnikova Olivier N. F. Cexus Andrey A. Zamyatnin Surinder M. Soond
author_sort	Paul A. Townsend
title	BH3-mimetics: recent developments in cancer therapy
title_short	BH3-mimetics: recent developments in cancer therapy
title_full	BH3-mimetics: recent developments in cancer therapy
title_fullStr	BH3-mimetics: recent developments in cancer therapy
title_full_unstemmed	BH3-mimetics: recent developments in cancer therapy
title_sort	bh3-mimetics: recent developments in cancer therapy
publisher	BMC
publishDate	2021
url	https://doaj.org/article/8ca444f31899451e9516bb1912adb4ea
work_keys_str_mv	AT paulatownsend bh3mimeticsrecentdevelopmentsincancertherapy AT mariavkozhevnikova bh3mimeticsrecentdevelopmentsincancertherapy AT oliviernfcexus bh3mimeticsrecentdevelopmentsincancertherapy AT andreyazamyatnin bh3mimeticsrecentdevelopmentsincancertherapy AT surindermsoond bh3mimeticsrecentdevelopmentsincancertherapy
_version_	1718429358832484352

BH3-mimetics: recent developments in cancer therapy

Ejemplares similares